– Promoting innovative new drug projects such as RNAi and T cell vaccines by establishing a new drug development and drug delivery system verification platform
Azos Bio (CEO Shin Jae-min), an artificial intelligence platform-based new drug development company, has developed its own artificial intelligence model (AiCPP) and ‘Cell Penetrating Peptide (CPP) and its uses’ discovered using the model. It was announced on the 3rd that it had applied for a patent.
Azos Bio has applied for a patent on new antigens discovered by an artificial intelligence model, and has been conducting research with professors In-ho Cho and Jeong-hyun Park at Ewha Womans University to develop an efficient delivery system.
The CPP discovered this time was confirmed to have excellent cell permeability and selective delivery properties to the endoplasmic reticulum (ER), and it was experimentally verified that it can be used as a safe drug carrier for T-cell antigen peptides and siRNA.
The newly developed AiCPP is an artificial intelligence platform developed in collaboration with Rescale, which provides a high-performance cloud computing platform. Using the Rescale platform, it analyzes more than 1 trillion peptide sequences in one day, reducing the cost and time of research and development. could be dramatically reduced.
As a drug delivery vehicle, CPP is recognized as a technology with advantages in safety, storage, and production costs compared to nanodevices or viral vectors, which are in the spotlight as nucleic acid delivery vehicles such as mRNA/siRNA. The drug delivery system market is expected to grow to approximately 170 trillion won ($158 billion) in 2027, as demand for drug delivery systems for mRNA vaccines or RNAi drugs increases as a treatment for COVID-19 or rare diseases. Recently, rapidly growing global biotech companies such as Moderna (market capitalization of $142 billion) and Allylam (market capitalization of $21 billion) are achieving great success through the combination of effective delivery systems and genomic drugs (mRNA, siRNA).
Jaemin Shin, CEO of AZothBio, said, “The ABDP® (AZothBio Biomedical Delivery Platform) established this time is a delivery system development platform applicable to small molecule compounds, mRNA, RNAi, etc., along with the new drug discovery artificial intelligence platform (AiDL® & BioDL®) to diversify profit models and new drugs. “We will be able to create opportunities for discovery and technology transfer,” he said, expressing his aspirations for growth.
Meanwhile, ASOSBIO Co., Ltd., a company specializing in artificial intelligence platforms for new drug development, has established a data platform (BioDL®) and an artificial intelligence integrated platform (AiDL®) and is using them for research and development. We recently expanded and relocated our headquarters and research center to the Hanam office building, establishing an in-situ R&D system that can immediately experimentally verify results predicted by artificial intelligence.
Rescale is a company that leads intelligent computing in digital R&D and provides more than 700 S/W and nearly unlimited H/W.
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news